News & Events

LE&RN applauds passage of groundbreaking LE education bill in New York State

LE&RN applauds passage of groundbreaking LE education bill in New York State

Pictured above: NYS Assemblymember Linda B. Rosenthal, LE&RN President and CEO William Repicci, and LE&RN Spokesperson Kathy Bates.

 

Dear LE&RN Supporting Members and allies,

On October 2, 2018, Governor Andrew Cuomo signed a first-in-the-nation Act, authored by LE&RN. The public health law is amended to mandate that the New York State Department of Health shall design an informational packet about lymphedema and shall require that every general hospital distribute such a packet to all patients at high risk of developing lymphedema. (You can read the full bill here and LE&RN's press release here.)

Our thanks go to Assemblymember Linda B. Rosenthal who first introduced this bill in the New York State (NYS) Assembly, and to Senator Martin J. Golden who championed it in the NYS Senate. And our thanks to Governor Andrew Cuomo who saw the importance of this bill and signed it into law.
 
One of the obstacles to lymphedema (LE) becoming a national priority has been its low profile among medical practitioners. With medical schools spending little time on the study of lymphatics, doctors are often slow or unable to diagnose LE. As a result, people at risk for the disease may be completely surprised by the onset of symptoms and lose valuable time in pursuing a treatment regimen. An informed person is an empowered person.
 
We will now work with LE&RN Chapters to bring this bill to State Houses across the country.
 
This bill is one part of a threefold strategy. It is equally important that doctors advise patients when LE is a risk prior to performing at-risk procedures. To address this, LE&RN and its partners have created the CME Physician Seminar in Lymphatic Disease Diagnosis and Treatment. And finally, we need to inspire healers by giving them new insurable treatments to dispense. This is why LE&RN will again be at the NIH this week to make the case that lymphatic research dollars need to be dramatically increased.
 
As an organization with an ambitious agenda impacting up to 250 million worldwide who suffer from lymphatic diseases, LE&RN relies on the activism and financial support of a loyal but relatively small membership.
 
To all those who have joined us, take pride in our successes. And if you know others who care about the lives of people with LE, but have stayed on the sidelines, what better time to enlist their support. If you haven't yet joined this important fight, I urge you to become a LE&RN Supporting Member today. There is a direct link between the number of people we can count as Supporting Members and our success.
 
Regards,


William Repicci
President & CEO, LE&RN